Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer.
Seongmin KimSanghoon LeeJin Hwa HongYoung Je ParkJae Yun SongJae Kwan LeeNak Woo LeePublished in: Journal of gynecologic oncology (2019)
HT boost treatment showed comparable disease outcomes with those observed with conventional BT in patients with advanced cervical cancer. HT could be a complementary boost protocol as a single modality or hybrid with BT in selected patients. Further studies with longer follow-up periods are warranted to confirm long-term outcomes.
Keyphrases
- high dose
- end stage renal disease
- randomized controlled trial
- low dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- radiation therapy
- type diabetes
- stem cell transplantation
- prognostic factors
- combination therapy
- metabolic syndrome
- skeletal muscle
- patient reported outcomes
- weight loss
- insulin resistance
- glycemic control
- locally advanced